Human Prostate Tissue Lysates

Pricing
Normal Lysates:  $125/100 ug
Tumor Lysates:   $175/100 ug
Nor./Tum. set: $270.00 (10% off)
Discounts
2-8    Vials  10%
9-20  Vials  15%
>20   Vials  20%

Introduction:

Over 95% of prostate cancers can be classified as adenocarcinomas. In general, the degree of tumor differentiation and abnormality of histologic growth pattern directly correlate with likelihood of metastases and with death. Because of marked variability in tumor differentiation from one microscopic field to another, many pathologists will report the range of differentiation among the malignant cells that are present in a biopsy (Gleason grade).

 

Human Prostate Cancer Lysates

Catalog Number

Diagnosis

Grade

Stage

TNM

Sex

Age

T3-001

Prostatic adenoma

n/a

n/a

n/a

M

74

T3-002

Prostatic hypertrophy

n/a

n/a

n/a

M

79

T3-003

Benign prostatic fibrosis

n/a

n/a

n/a

M

72

T3-004

Prostatic fibroadenoma

n/a

n/a

n/a

M

40

T3-005

Normal prostate

n/a

n/a

n/a

M

40

T3-006

Normal prostate

n/a

n/a

n/a

M

24

T3-007

Prostatic hyperplasia

n/a

n/a

n/a

M

65

T3-008

Prostatic fibroma

n/a

n/a

n/a

M

68

T3-009

Prostatic hypertrophy

n/a

n/a

n/a

M

81

T3-010

Normal prostate

n/a

n/a

n/a

M

24

T3-011

Prostatic hypertrophy

n/a

n/a

n/a

M

70

T3-012

Prostatic hypertrophy

n/a

n/a

n/a

M

84

T3-013

Prostatic fibroma

n/a

n/a

n/a

M

69

T3-014

Prostatic hypertrophy

n/a

n/a

n/a

M

85

T3-015

Prostatic fibroma

n/a

n/a

n/a

M

69

T3-016

Normal prostate

n/a

n/a

n/a

M

50

T3-017

Normal prostate

n/a

n/a

n/a

M

65

T3-018

Prostatic hypertrophy

n/a

n/a

n/a

M

80

T3-019

Normal prostate

n/a

n/a

n/a

M

37

T3-020

Normal prostate

n/a

n/a

n/a

M

61

T3-021

Normal prostate

n/a

n/a

n/a

M

32

T3-022

Normal prostate

n/a

n/a

n/a

M

40

T3-023

Prostatic Adenocarcinoma

1

n/a

n/a

M

79

T3-024

Prostatic Adenocarcinoma

2

n/a

n/a

M

77

T3-025

Prostatic Adenocarcinoma

3

III

T3aNxMx

M

65

T3-026

Prostatic Adenocarcinoma

2

n/a

n/a

M

66

T3-027

Prostatic Adenocarcinoma

1

n/a

n/a

M

63

T3-028

Prostatic Adenocarcinoma

1

n/a

n/a

M

76

T3-029

Prostatic Adenocarcinoma

2

n/a

n/a

M

66

T3-030

Prostatic Adenocarcinoma

2

n/a

n/a

M

80

T3-031

Prostatic Adenocarcinoma

2

n/a

n/a

M

71

T3-032

Prostatic Adenocarcinoma

1

III

T3bN0M0

M

65

T3-033

Prostatic Adenocarcinoma

1

n/a

n/a

M

69

T3-034

Prostatic Adenocarcinoma

2

n/a

n/a

M

78

T3-035

Prostatic Adenocarcinoma

n/a

n/a

n/a

M

43

T3-036

Prostatic Adenocarcinoma

2

II

T2N0M0

M

62

T3-037

Prostatic Adenocarcinoma

3

III

T3bNxMx

M

64

T3-038

Prostatic Adenocarcinoma

1

n/a

n/a

M

74

T3-039

Prostatic Adenocarcinoma

2

n/a

n/a

M

47

T3-040

Prostatic Adenocarcinoma

3

n/a

n/a

M

71

T3-041

Prostatic Adenocarcinoma

2

n/a

n/a

M

87

T3-042

Prostatic Adenocarcinoma

2

n/a

n/a

M

71

 

References:

Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 (1): 58-64, 1974.

Gleason DF: Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M: Urologic Pathology: The Prostate. Philadelphia, Pa: Lea and Febiger, 1977, pp 171-197.